Working… Menu

Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02866032
Recruitment Status : Completed
First Posted : August 15, 2016
Last Update Posted : October 6, 2020
Information provided by (Responsible Party):
Moberg Pharma AB

Brief Summary:

The primary objective of this study is to evaluate the efficacy of topical MOB015B in patients with mild to moderate distal subungual onychomycosis (DSO).

The secondary objective is to evaluate the safety of topical MOB015B in patients with mild to moderate DSO.

Condition or disease Intervention/treatment Phase
Distal Subungual Onychomycosis Drug: MOB015B Drug: Ciclopirox 80 mg/g Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 452 participants
Official Title: A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
Study Start Date : September 2016
Actual Primary Completion Date : June 10, 2020
Actual Study Completion Date : June 10, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: MOB015B Drug: MOB015B
Active Comparator: Ciclopirox 80 mg/g Drug: Ciclopirox 80 mg/g

Primary Outcome Measures :
  1. Complete cure of the target nail defined as negative fungal culture of dermatophytes, negative direct KOH microscopy and 0% clinical disease involvement at Week 52 [ Time Frame: Week 52 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  1. Males or females 18 - 75 years of age
  2. Distal subungual onychomycosis (DSO) of at least one of the great toenail(s) affecting 20% to 60% of the target nail
  3. Positive culture for dermatophytes
  4. Signed written informed consent

Exclusion Criteria:

  1. Proximal subungual onychomycosis
  2. Distal subungual onychomycosis of both great toenails where involvement has extended into the proximal portion of the target nail (unaffected proximal nail is less than 3 mm)
  3. Target toenail thickness more than 3 mm
  4. "Spike" of onychomycosis extending to eponychium of the target toenail
  5. Presence of dermatophytoma (defined as thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail
  6. Other conditions than DSO known to cause abnormal nail appearance
  7. Presence of toenail infection other than dermatophytes
  8. Previous target toenail surgery with any residual disfigurement
  9. Topical treatment of the nails with other antifungal medication or medical device within 6 weeks before screening/Visit 1
  10. Systemic use of antifungal treatment within 6 months before screening/ Visit 1
  11. Severe moccasin tinea pedis
  12. Signs of severe peripheral circulatory insufficiency
  13. Uncontrolled diabetes mellitus
  14. Known immunodeficiency
  15. Participation in another clinical trial with an investigational drug or device during the previous 3 months before Baseline/ Visit 2
  16. Known allergy to any of the tested treatment products
  17. A positive pregnancy test indicating pregnancy in a woman of childbearing potential at Baseline/ Visit 2
  18. Females who are pregnant or breastfeeding
  19. Pre-menopausal (last menstruation ≤ 1 year prior to screening) sexually active women who are of childbearing potential and are not practicing an acceptable method of birth control, or do not plan to continue practicing an acceptable method of birth control throughout the trial
  20. Patients previously randomized in this study
  21. History of, or current drug or alcohol abuse
  22. Psychiatric condition that might limit the participation in the study and/or that lead to the assumption that the patient's ability to completely understand the consequences of consent is missing
  23. Close affiliation with the investigator (e.g. a close relative) or persons working at a study site, or patient who is an employee of the sponsor's company
  24. Patients who are institutionalized because of legal or regulatory order
  25. Any diseases or circumstances in which the patient should not participate in the study in the opinion of the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02866032

Layout table for location information
Multiple Locations, Germany
Multiple Locations, Poland
United Kingdom
Multiple Locations, United Kingdom
Sponsors and Collaborators
Moberg Pharma AB
Layout table for additonal information
Responsible Party: Moberg Pharma AB Identifier: NCT02866032    
Other Study ID Numbers: MOB015B-III
First Posted: August 15, 2016    Key Record Dates
Last Update Posted: October 6, 2020
Last Verified: October 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Infectious
Nail Diseases
Skin Diseases
Antifungal Agents
Anti-Infective Agents